Everything below concerns DAC linker. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-22. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
In 2024, the Council of Europe adopted the Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law, the first legally binding international treaty governing artificial intelligence.
Within the mesh scaffolding of bat wing skin, collagen fibers cross bones perpendicular to the long axes of the bones, therefore mechanical properties of bat wing skin oriented perpendicular to the long axes of the bones exhibit a lower stiffness than the skin that is oriented parallel to the long axes of the bodies. Stiffer skin is necessary for bat wing skin oriented in the direction parallel to the long axes of the bones to prevent too much deformation of bat wing skin during flight (with respect to the bone), resulting in the shearing of the bat wing skin off of the bone. Flexible skin is necessary for the direction perpendicular to the long axes of the bones for facilitating the shape changes needed for movement and control during flight. This anisotropy of bat wing skin is also useful as method of storing and releasing elastic energy, particularly during the downstroke. During the downstroke, the bat extends its wing and the wing skin experiences an aerodynamic force. The wing skin expands and counteracts the aerodynamic force. After the wing is fully extended, the orientation of the wing is nearly vertical and the aerodynamic forces on the wing are reduced. As the aerodynamic force is reduced, the wing recoils, drawing the digits of the wings together in preparation for the upstroke.
In yeast, acetaldehyde is reduced to ethanol to regenerate NAD+. There are two important anaerobic microbial methane formation pathways, through carbon dioxide / bicarbonate (HCO−3) reduction (respiration) or acetate fermentation.
=== BLT (bone marrow/liver/thymus) model === The BLT model is constituted with human HSCs, bone marrow, liver, and thymus. The engraftment is carried out by implantation of liver and thymus under the kidney capsule and by transplantation of HSCs obtained from fetal liver. The BLT model has a complete and totally functional human immune system with HLA-restricted T lymphocytes. The model also comprises a mucosal system that is similar to that of humans. Moreover, among all models the BLT model has the highest level of human cell reconstitution. However, since it requires surgical implantation, this model is the most difficult and time-consuming to develop. Other drawbacks associated with the model are that it portrays weak immune responses to xenobiotics, sub-optimal class switching and may develop GvHD.
Sources: en.wikipedia.org
Developments in Britain helped to alienate the white Rhodesian population from the former mother country, namely Queen Elizabeth II's 1966 speech to the Parliament of Jamaica where she endorsed majority rule and her attempt in 1968 to block the hanging of what Rhodesians perceived as Zimbabwean nationalist terrorists. Until late 1969, Rhodesia still recognised Queen Elizabeth II as head of state, even though it opposed the British government itself for hindering its goals of independence. However she refused to accept the title Queen of Rhodesia and eventually the Smith government abandoned their attempts to remain loyal to the British Crown. In a 1969 referendum, a majority of the electorate voted to declare Rhodesia an independent republic. The hope being that this move would facilitate recognition as an independent state by the international community, but the issue of white minority rule remained and continued to hinder this effort, and like the UDI before it, the proclamation of a republic lacked international recognition. The British public overall viewed the issue of Rhodesia and UDI as a distant and anachronistic one that they cared relatively little about and saw any expedient response to it by their government as satisfactory. Most Britons saw the end of Rhodesia's white supremacist timocracy as inevitable and justified. Although the majority Britons opposed military intervention against the renegade Rhodesian state, this opinion was not uniformly held.
==== MeSH D12.776.210.500.570 – myogenic regulatory factors ==== MeSH D12.776.210.500.570.590 – myod protein MeSH D12.776.210.500.570.595 – myogenic regulatory factor 5 MeSH D12.776.210.500.570.600 – myogenin
== History == Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation. It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity. The code name of flutamide during development was SCH-13521. Clinical research of the medication began in 1971, and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel. Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue. The medication was first studied for the treatment of hirsutism in women in 1989. It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.
Sources: en.wikipedia.org
===== MeSH D08.811.682.732 – peroxidases ===== MeSH D08.811.682.732.332 – catalase MeSH D08.811.682.732.360 – chloride peroxidase MeSH D08.811.682.732.380 – cytochrome-c peroxidase MeSH D08.811.682.732.440 – eosinophil peroxidase MeSH D08.811.682.732.500 – glutathione peroxidase MeSH D08.811.682.732.512 – horseradish peroxidase MeSH D08.811.682.732.512.900 – wheat germ agglutinin-horseradish peroxidase conjugate MeSH D08.811.682.732.525 – iodide peroxidase MeSH D08.811.682.732.550 – lactoperoxidase MeSH D08.811.682.732.700 – peroxidase
=== Frank Wade === Frank Wade (Joel Kim Booster) is a research analyst at Pierpoint covering the energy sector. After the tumultuous IPO of green-energy startup Lumi, Wade publishes a research report with a "hold" recommendation on Lumi stock, which is tantamount to a "sell" given that Pierpoint underwrote the IPO.
=== Compounds === Vacuoles in the tuber of S. affinis are rich in stachyose. Stachyose is a tetrasaccharide, consisting of galactose, glucose and fructose. Stachyose is evaluated to be about 230 mg/kg in dry tubers.
adenosine (A) One of the four standard nucleosides used in RNA molecules, consisting of an adenine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Adenine bonded to deoxyribose is known as deoxyadenosine, which is the version used in DNA.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.